282 related articles for article (PubMed ID: 9119167)
1. Current issues in viral assays and viral clearance evaluation.
Lubiniecki AS
Dev Biol Stand; 1996; 88():9-11. PubMed ID: 9119167
[TBL] [Abstract][Full Text] [Related]
2. Process changes and their effect on process evaluation for viral clearance.
Marcus-Sekura C
Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
[TBL] [Abstract][Full Text] [Related]
3. Process scale considerations in evaluation studies and scale-up.
Walter JK; Werz W; Berthold W
Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
[TBL] [Abstract][Full Text] [Related]
4. Risk reduction in biotherapeutic products.
Ill CR; Dehghani H
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of anti-viral filters.
Hughes B; Bradburne A; Sheppard A; Young D
Dev Biol Stand; 1996; 88():91-8. PubMed ID: 9119168
[TBL] [Abstract][Full Text] [Related]
6. Evolution of approaches to viral safety issues for biological products.
Lubiniecki AS
PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
[TBL] [Abstract][Full Text] [Related]
7. A comparison of methods for the estimation of retroviral burden.
Bierley ST; Raineri R; Poiley JA; Morgan EM
Dev Biol Stand; 1996; 88():163-5. PubMed ID: 9119132
[TBL] [Abstract][Full Text] [Related]
8. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
[TBL] [Abstract][Full Text] [Related]
9. Detection of adventitious viruses in biologicals--a rare occurrence.
Nims RW
Dev Biol (Basel); 2006; 123():153-64; discussion 183-97. PubMed ID: 16566443
[TBL] [Abstract][Full Text] [Related]
10. Issues related to harmonization of testing requirements for viral safety.
Hayakawa T
Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
[TBL] [Abstract][Full Text] [Related]
11. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
[TBL] [Abstract][Full Text] [Related]
12. Strategies for viral removal and inactivation.
Burstyn DG; Hageman TC
Dev Biol Stand; 1996; 88():73-9. PubMed ID: 9119165
[TBL] [Abstract][Full Text] [Related]
13. Considerations in performing virus spiking experiments and process validation studies.
Darling AJ
Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
[TBL] [Abstract][Full Text] [Related]
14. Adventitious agents from animal-derived raw materials--a method of risk assessment.
Foster LG
Dev Biol Stand; 1996; 88():283-90. PubMed ID: 9119152
[TBL] [Abstract][Full Text] [Related]
15. Issues of biological assays for viral vaccines.
Lee CK
Dev Biol Stand; 1996; 88():41-7. PubMed ID: 9119161
[TBL] [Abstract][Full Text] [Related]
16. Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE).
Rohwer RG
Dev Biol Stand; 1996; 88():247-56. PubMed ID: 9119146
[TBL] [Abstract][Full Text] [Related]
17. Detection breadth and limits for potential adventitious/endogenous contaminants in biopharmaceutical processes: a reality check for innovative methods.
Duncan P; McKerral L; Feng S; Tsai PK
Dev Biol (Basel); 2006; 126():283-90; discussion 327. PubMed ID: 17058504
[TBL] [Abstract][Full Text] [Related]
18. Analysis of viral clearance unit operations for monoclonal antibodies.
Miesegaes G; Lute S; Brorson K
Biotechnol Bioeng; 2010 Jun; 106(2):238-46. PubMed ID: 20073086
[TBL] [Abstract][Full Text] [Related]
19. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider.
Vicari G
Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625
[TBL] [Abstract][Full Text] [Related]
20. Scope and practicality of in vivo testing for adventitious agents.
Whiteman MD
Dev Biol (Basel); 2006; 123():147-52; discussion 183-97. PubMed ID: 16566442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
